Strict Tysabri Risk Management Plan Drives Panel Support For Crohn’s

A highly restrictive risk management program for Biogen Idec/Elan's Tysabri swayed a joint advisory panel to recommend the product's approval for a Crohn's disease indication July 31 despite modest efficacy data and remaining safety concerns